Advertisement
Australia markets close in 1 hour 31 minutes
  • ALL ORDS

    8,074.20
    +8.70 (+0.11%)
     
  • ASX 200

    7,803.40
    +10.10 (+0.13%)
     
  • AUD/USD

    0.6576
    -0.0025 (-0.37%)
     
  • OIL

    78.03
    -0.35 (-0.45%)
     
  • GOLD

    2,326.50
    +2.30 (+0.10%)
     
  • Bitcoin AUD

    95,232.05
    -1,117.57 (-1.16%)
     
  • CMC Crypto 200

    1,303.46
    -61.66 (-4.52%)
     
  • AUD/EUR

    0.6120
    -0.0011 (-0.17%)
     
  • AUD/NZD

    1.0971
    -0.0017 (-0.15%)
     
  • NZX 50

    11,788.37
    -12.41 (-0.11%)
     
  • NASDAQ

    18,091.45
    -2.12 (-0.01%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • Dow Jones

    38,884.26
    +31.99 (+0.08%)
     
  • DAX

    18,430.05
    +254.84 (+1.40%)
     
  • Hang Seng

    18,410.20
    -69.17 (-0.37%)
     
  • NIKKEI 225

    38,269.16
    -565.94 (-1.46%)
     

New Strong Sell Stocks for February 14th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

ConforMIS CFMS is a medical technology company which develops, manufacture and sells joint replacement implants. The Zacks Consensus Estimate for its current year earnings has been revised 200% downward over the last 60 days.

JD.com JD operates as an online direct sales company in China. The Zacks Consensus Estimate for its current year earnings has been revised 2.4% downward over the last 60 days.

Paramount Gold Nevada PZG engages in the acquisition, exploration, and development of gold, silver, and precious metal properties primarily in Mexico. The Zacks Consensus Estimate for its current year earnings has been revised 16.7% downward over the last 60 days.

ADVERTISEMENT

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Paramount Gold Nevada Corp. (PZG) : Free Stock Analysis Report
 
JD.com, Inc. (JD) : Free Stock Analysis Report
 
ConforMIS, Inc. (CFMS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research